AU2016325601C1 - 3-hydroxy-quinazoline-2,4-dione derivatives and their use as nuclease modulators - Google Patents

3-hydroxy-quinazoline-2,4-dione derivatives and their use as nuclease modulators Download PDF

Info

Publication number
AU2016325601C1
AU2016325601C1 AU2016325601A AU2016325601A AU2016325601C1 AU 2016325601 C1 AU2016325601 C1 AU 2016325601C1 AU 2016325601 A AU2016325601 A AU 2016325601A AU 2016325601 A AU2016325601 A AU 2016325601A AU 2016325601 C1 AU2016325601 C1 AU 2016325601C1
Authority
AU
Australia
Prior art keywords
substituted
unsubstituted
independently
nhc
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016325601A
Other languages
English (en)
Other versions
AU2016325601B2 (en
AU2016325601A1 (en
Inventor
Timothy GAHMAN
Richard Kolodner
Andrew Shiau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Original Assignee
Ludwig Institute for Cancer Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research Ltd filed Critical Ludwig Institute for Cancer Research Ltd
Publication of AU2016325601A1 publication Critical patent/AU2016325601A1/en
Application granted granted Critical
Publication of AU2016325601B2 publication Critical patent/AU2016325601B2/en
Publication of AU2016325601C1 publication Critical patent/AU2016325601C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
AU2016325601A 2015-09-25 2016-09-26 3-hydroxy-quinazoline-2,4-dione derivatives and their use as nuclease modulators Ceased AU2016325601C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562233110P 2015-09-25 2015-09-25
US62/233,110 2015-09-25
PCT/IB2016/001473 WO2017051251A1 (en) 2015-09-25 2016-09-26 3-hydroxy-quinazoline-2,4-dione derivatives and their use as nuclease modulators

Publications (3)

Publication Number Publication Date
AU2016325601A1 AU2016325601A1 (en) 2018-03-29
AU2016325601B2 AU2016325601B2 (en) 2021-04-15
AU2016325601C1 true AU2016325601C1 (en) 2022-03-31

Family

ID=57256366

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016325601A Ceased AU2016325601C1 (en) 2015-09-25 2016-09-26 3-hydroxy-quinazoline-2,4-dione derivatives and their use as nuclease modulators

Country Status (7)

Country Link
US (1) US11253521B2 (https=)
EP (1) EP3353154B3 (https=)
JP (1) JP7163180B2 (https=)
CN (1) CN108430978B (https=)
AU (1) AU2016325601C1 (https=)
CA (1) CA2998294C (https=)
WO (1) WO2017051251A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202113610D0 (en) 2021-09-23 2021-11-10 Francis Crick Institute Ltd Novel method
CN114539148A (zh) * 2022-01-25 2022-05-27 北京英飞智药科技有限公司 一种环状n-羟基酰亚胺类化合物及其用途
CN114539080A (zh) * 2022-03-02 2022-05-27 八叶草健康产业研究院(厦门)有限公司 一种2-(2-氨基-6-氯苯基)-乙酸钠的制备方法
WO2023219958A2 (en) * 2022-05-09 2023-11-16 The Regents Of The University Of California Methods for the treatment of nlrp3 related disorders
WO2025172707A1 (en) * 2024-02-13 2025-08-21 Merck Patent Gmbh Heterocyclic compounds modulating exonuclease 1 (exo1)
WO2025172706A1 (en) * 2024-02-13 2025-08-21 Merck Patent Gmbh Compounds modulating flap endonuclease (fen1)
EP4686475A1 (en) 2024-07-31 2026-02-04 Fundação D. Anna De Sommer Champalimaud E Dr. Carlos Montez Champalimaud - Centro De Investigação Da Fundação Champalimaud Xpg inhibitors for use in the treatment of cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0316630A1 (en) * 1987-10-27 1989-05-24 Warner-Lambert Company Novel fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
WO1999021840A1 (en) * 1997-10-28 1999-05-06 Warner-Lambert Company Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents
WO2001070737A2 (en) * 2000-03-20 2001-09-27 Sepracor, Inc. Therapeutic heterocyclic compounds for the treatment of asthma and allergy and use thereof
WO2012004731A1 (en) * 2010-07-06 2012-01-12 Sanofi Indolizine derivatives, process for the preparation thereof and therapeutic use thereof
WO2012047993A2 (en) * 2010-10-05 2012-04-12 Regents Of The University Of Minnesota N-hydroxypyrimidine-2,4-diones as inhibitors of hiv and hcv

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
CS266762B1 (cs) * 1988-06-15 1990-01-12 Pazdera Pavel 3-Subst.ituované 4-lmlno-l ,2,3,4-tetrano-l ,2,3,4-tetra-hydrochlnazolin-2-thiony a způsob jejich přípravy
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US7947691B2 (en) 2004-07-21 2011-05-24 Athersys, Inc. Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof
CN105669653B (zh) 2016-03-14 2018-08-21 山东大学 一种n-羟基杂环并嘧啶二酮类衍生物及其制备方法与应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0316630A1 (en) * 1987-10-27 1989-05-24 Warner-Lambert Company Novel fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
WO1999021840A1 (en) * 1997-10-28 1999-05-06 Warner-Lambert Company Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents
WO2001070737A2 (en) * 2000-03-20 2001-09-27 Sepracor, Inc. Therapeutic heterocyclic compounds for the treatment of asthma and allergy and use thereof
WO2012004731A1 (en) * 2010-07-06 2012-01-12 Sanofi Indolizine derivatives, process for the preparation thereof and therapeutic use thereof
WO2012047993A2 (en) * 2010-10-05 2012-04-12 Regents Of The University Of Minnesota N-hydroxypyrimidine-2,4-diones as inhibitors of hiv and hcv

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CAS accession no. 1988:204459, GHONEIM, K. M. ET AL: "Novel 2-substituted aminonicotinhydroxamic acids", *
CAS accession no. 1991:164266, PAZDERA, PAVEL ET AL: "Preparation of 3-substituted 4-imino-1,2,3,4-tetrahydroquinazoline-2- thiones" *
CHAPMAN TIMOTHY M ET AL, "N-Hydroxyimides and hydroxypyrimidinones as inhibitors of the DNA repair complex ERCC1", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, (2015-08-14), vol. 25, no. 19, pages 4104 - 4108 *
CIANCI C ET AL, "IDENTIFICATION OF N-HYDROXAMIC ACID AND N-HYDROXYIMIDE COMPOUNDS THAT INHIBIT THE INFLUENZA VIRUS POLYMERASE", ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, (1996-12-01), vol. 7, no. 6, pages 353 - 360 *
E. B. LANSDON ET AL, "Structural and Binding Analysis of Pyrimidinol Carboxylic Acid and N-Hydroxy Quinazolinedione HIV-1 RNase H Inhibitors", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, US, (2011-04-04), vol. 55, no. 6, pages 2905 - 2915 *
KOU-YI TSERNG L BAUER, "3-HYDROXYPYRIDOPYRIMIDINE-2,4(1H,3H)DIONES", JOURNAL OF HETEROCYCLIC CHEMISTRY, WILEY-BLACKWELL PUBLISHING, INC, US, (1972-12-01), vol. 9, no. 6, ISSN 0022-152X, pages 1433 - 1435 *
TUMEY L N ET AL, "The identification and optimization of a N-hydroxy urea series of flap endonuclease 1 inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 15, no. 2, pages 277 - 281, (2005-01-17) *

Also Published As

Publication number Publication date
US20200237763A1 (en) 2020-07-30
CA2998294C (en) 2023-09-12
CN108430978A (zh) 2018-08-21
CA2998294A1 (en) 2017-03-30
EP3353154B3 (en) 2022-10-19
WO2017051251A1 (en) 2017-03-30
CN108430978B (zh) 2022-11-22
JP7163180B2 (ja) 2022-10-31
US11253521B2 (en) 2022-02-22
AU2016325601B2 (en) 2021-04-15
AU2016325601A1 (en) 2018-03-29
JP2018535930A (ja) 2018-12-06
EP3353154B1 (en) 2020-08-19
EP3353154A1 (en) 2018-08-01

Similar Documents

Publication Publication Date Title
AU2016325601C1 (en) 3-hydroxy-quinazoline-2,4-dione derivatives and their use as nuclease modulators
AU2017358901B2 (en) Compounds and methods for modulating interleukin-2-inducible T-cell kinase
ES2676826T3 (es) Compuestos basados en imidazo[1,2-b]piridazina, composiciones que los comprenden y usos de los mismos
CA2915561C (en) Novel substituted bicyclic compounds as bromodomain inhibitors
CA3222841A1 (en) Use of atr inhibitors in combination with parp inhibitors for treating cancer
CN109071455B (zh) 用于调节布鲁顿酪氨酸激酶的化合物及方法
ES3041367T3 (en) Eaat2 activators and methods of using thereof
CA3021324A1 (en) Erbb inhibitors and uses thereof
WO2021183791A1 (en) Wnt/cbp/catenin signaling pathway inhibitors and uses thereof
US11584760B2 (en) Dithio ETP derivatives
US10189824B2 (en) Pyrimidine-diamine dual HSP90/TRAP1 inhibitors
US11117894B2 (en) Pyridopyrazine compounds and uses thereof
EP4387617A1 (en) Acid ceramidase inhibitors and uses thereof
CA3017567C (en) Compounds and methods for modulating bruton's tyrosine kinase
WO2015196144A2 (en) Androgen receptor antagonists
WO2020150638A1 (en) Berbamine derivatives and methods of use thereof
HK40014009B (en) Compounds and methods for modulating interleukin-2-inducible t-cell kinase
HK40014009A (en) Compounds and methods for modulating interleukin-2-inducible t-cell kinase
HK1262897A1 (en) Compounds and methods for modulating bruton's tyrosine kinase

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 11 NOV 2021

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 11 NOV 2021

MK14 Patent ceased section 143(a) (annual fees not paid) or expired